OA16774A - Multiple myeloma treatment. - Google Patents
Multiple myeloma treatment. Download PDFInfo
- Publication number
- OA16774A OA16774A OA1201300456 OA16774A OA 16774 A OA16774 A OA 16774A OA 1201300456 OA1201300456 OA 1201300456 OA 16774 A OA16774 A OA 16774A
- Authority
- OA
- OAPI
- Prior art keywords
- cells
- subject
- compound
- cyt387
- multiple myeloma
- Prior art date
Links
- 206010035226 Plasma cell myeloma Diseases 0.000 title claims abstract description 140
- 201000009251 multiple myeloma Diseases 0.000 title claims abstract description 25
- 150000001875 compounds Chemical class 0.000 claims abstract description 86
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 7
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N CYT387 Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 claims description 122
- -1 morpholino, thiomorpholinyl Chemical group 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 23
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 15
- 229960001467 bortezomib Drugs 0.000 claims description 15
- 239000000651 prodrug Substances 0.000 claims description 10
- 229940002612 prodrugs Drugs 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000035899 viability Effects 0.000 claims description 7
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 230000001965 increased Effects 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 201000002674 obstructive nephropathy Diseases 0.000 claims description 2
- 210000004027 cells Anatomy 0.000 description 156
- 201000000050 myeloid neoplasm Diseases 0.000 description 115
- 239000000203 mixture Substances 0.000 description 51
- 230000002401 inhibitory effect Effects 0.000 description 47
- 230000000694 effects Effects 0.000 description 31
- 201000010099 disease Diseases 0.000 description 29
- 239000000725 suspension Substances 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 20
- 239000003112 inhibitor Substances 0.000 description 19
- 229940079593 drugs Drugs 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 17
- 230000011664 signaling Effects 0.000 description 17
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 16
- 102100005499 PTPRC Human genes 0.000 description 16
- 101700059076 PTPRC Proteins 0.000 description 16
- 229960001924 melphalan Drugs 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 210000004271 bone marrow stromal cells Anatomy 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 102100019388 SOAT1 Human genes 0.000 description 14
- 101700025022 SOAT1 Proteins 0.000 description 14
- 101710028406 satA Proteins 0.000 description 14
- 230000006907 apoptotic process Effects 0.000 description 12
- 230000037361 pathway Effects 0.000 description 12
- 102100019516 JAK2 Human genes 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 206010059512 Apoptosis Diseases 0.000 description 10
- 101700016050 JAK2 Proteins 0.000 description 10
- 101700067074 MAPK Proteins 0.000 description 10
- 101710041325 MAPKAPK2 Proteins 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 101710024887 rl Proteins 0.000 description 10
- 101700045897 spk-1 Proteins 0.000 description 10
- 101700006234 AKT1 Proteins 0.000 description 9
- 102100001248 AKT1 Human genes 0.000 description 9
- XJMOSONTPMZWPB-UHFFFAOYSA-M Propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000022131 cell cycle Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 210000001185 Bone Marrow Anatomy 0.000 description 8
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 8
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 102100003279 CD38 Human genes 0.000 description 7
- 101700044948 CD38 Proteins 0.000 description 7
- 108091000081 Phosphotransferases Proteins 0.000 description 7
- 102000001253 Protein Kinases Human genes 0.000 description 7
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 7
- 230000001351 cycling Effects 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 239000002609 media Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 108091007934 protein kinase B family Proteins 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 239000000969 carrier Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 230000002335 preservative Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 230000001225 therapeutic Effects 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 101700055524 VME1 Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 102000004965 antibodies Human genes 0.000 description 5
- 108090001123 antibodies Proteins 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 101700045377 mvp1 Proteins 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000004083 survival Effects 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- 108050008874 Annexins Proteins 0.000 description 4
- 102000000412 Annexins Human genes 0.000 description 4
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 4
- 108091007936 ERK family Proteins 0.000 description 4
- 210000004011 Plasma Cells Anatomy 0.000 description 4
- 239000004698 Polyethylene (PE) Substances 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 4
- 230000003000 nontoxic Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 230000036961 partial Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000000865 phosphorylative Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 210000001519 tissues Anatomy 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 101710039984 9.1 Proteins 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 3
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 3
- 101710003804 CD40LG Proteins 0.000 description 3
- 102100003729 CD40LG Human genes 0.000 description 3
- 244000089742 Citrus aurantifolia Species 0.000 description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 3
- 230000004668 G2/M phase Effects 0.000 description 3
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 3
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 3
- 102100019518 JAK3 Human genes 0.000 description 3
- 101700007593 JAK3 Proteins 0.000 description 3
- 206010024324 Leukaemias Diseases 0.000 description 3
- IDINUJSAMVOPCM-UHFFFAOYSA-N N-[2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 210000002536 Stromal Cells Anatomy 0.000 description 3
- 235000015450 Tilia cordata Nutrition 0.000 description 3
- 235000011941 Tilia x europaea Nutrition 0.000 description 3
- NWGKJDSIEKMTRX-AAZCQSIUSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229960002706 gusperimus Drugs 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003834 intracellular Effects 0.000 description 3
- 238000009114 investigational therapy Methods 0.000 description 3
- 239000004571 lime Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000001686 pro-survival Effects 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 230000000699 topical Effects 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- PDOQBOJDRPLBQU-QMMMGPOBSA-N 5-chloro-2-N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1N=CC(F)=CN=1)C(N=1)=NC=C(Cl)C=1NC=1C=C(C)NN=1 PDOQBOJDRPLBQU-QMMMGPOBSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 208000003432 Bone Disease Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 229960005069 Calcium Drugs 0.000 description 2
- 229960003563 Calcium Carbonate Drugs 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 Etoposide Drugs 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 102000004218 Insulin-like growth factor I Human genes 0.000 description 2
- 108090000723 Insulin-like growth factor I Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 229940067606 Lecithin Drugs 0.000 description 2
- 102100015275 MYOM2 Human genes 0.000 description 2
- 101700036747 MYOM2 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 210000003928 Nasal Cavity Anatomy 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229940067631 Phospholipids Drugs 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000036462 Unbound Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 230000001028 anti-proliferant Effects 0.000 description 2
- 230000001640 apoptogenic Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000005251 aryl acyl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 239000005441 aurora Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- PTSZMMLYAGLVQJ-UHFFFAOYSA-N ethyl 4-(2-chloropyrimidin-4-yl)benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CC=NC(Cl)=N1 PTSZMMLYAGLVQJ-UHFFFAOYSA-N 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000003394 haemopoietic Effects 0.000 description 2
- 125000003106 haloaryl group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 230000003211 malignant Effects 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- 102000005614 monoclonal antibodies Human genes 0.000 description 2
- 108010045030 monoclonal antibodies Proteins 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 230000000010 osteolytic Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000001187 sodium carbonate Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- NWJQLQGQZSIBAF-MLAUYUEBSA-N tacrolimus hydrate Chemical compound O.C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 NWJQLQGQZSIBAF-MLAUYUEBSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N β-Alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FIWSRSRCWYARAJ-SQOFCNSWSA-N (2R,3R,4R,5S)-hexane-1,2,3,4,5,6-hexol;(Z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O FIWSRSRCWYARAJ-SQOFCNSWSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N (2S)-2-acetamido-N-[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-4-methylpentanamide Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 description 1
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
- CTPOHARTNNSRSR-APJZLKAGSA-N 4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoic acid Chemical compound O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC(O)=O CTPOHARTNNSRSR-APJZLKAGSA-N 0.000 description 1
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N 5-hydroxylysine Chemical compound NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 102000000132 Alpha tubulin Human genes 0.000 description 1
- 108050008484 Alpha tubulin Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 240000005781 Arachis hypogaea Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 229960002170 Azathioprine Drugs 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N Boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N Bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 229940030609 CALCIUM CHANNEL BLOCKERS Drugs 0.000 description 1
- 102100005858 CCNA2 Human genes 0.000 description 1
- 102100019530 CCND2 Human genes 0.000 description 1
- 102100005310 CTLA4 Human genes 0.000 description 1
- 101700054183 CTLA4 Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229960004424 Carbon Dioxide Drugs 0.000 description 1
- 229940063834 Carboxymethylcellulose Sodium Drugs 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960003260 Chlorhexidine Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 108010058544 Cyclin D2 Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- 229960000684 Cytarabine Drugs 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 229940030606 DIURETICS Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N Dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 229940087091 Dichlorotetrafluoroethane Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N Digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N Diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N Epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Exidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N Felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 1
- 229960003580 Felodipine Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 229940074045 Glyceryl Distearate Drugs 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960002897 Heparin Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229960002591 Hydroxyproline Drugs 0.000 description 1
- 229940102223 Injectable Solution Drugs 0.000 description 1
- 229940102213 Injectable Suspension Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940100601 Interleukin-6 Drugs 0.000 description 1
- 241001527806 Iti Species 0.000 description 1
- 108010019437 Janus Kinase 2 Proteins 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline zwitterion Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 101700064702 LABA Proteins 0.000 description 1
- 229960004873 LEVOMENTHOL Drugs 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229940041616 Menthol Drugs 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000028664 Microtubules Human genes 0.000 description 1
- 108091022031 Microtubules Proteins 0.000 description 1
- 210000004688 Microtubules Anatomy 0.000 description 1
- 206010060880 Monoclonal gammopathy Diseases 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 206010028576 Myeloproliferative disease Diseases 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 101710040692 PARPBP Proteins 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 208000002774 Paraproteinemias Diseases 0.000 description 1
- 102000015094 Paraproteins Human genes 0.000 description 1
- 108010064255 Paraproteins Proteins 0.000 description 1
- 206010062081 Plasma cell disease Diseases 0.000 description 1
- 206010035228 Plasma cell neoplasms Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 206010035485 Plasmacytosis Diseases 0.000 description 1
- 231100000614 Poison Toxicity 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940068965 Polysorbates Drugs 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M Potassium bicarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940072288 Prograf Drugs 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 229940099538 Rapamune Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N Salbutamol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- PHWXUGHIIBDVKD-UHFFFAOYSA-N Sitaxentan Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)CC=2C(=CC=3OCOC=3C=2)C)=C1Cl PHWXUGHIIBDVKD-UHFFFAOYSA-N 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 108020004459 Small Interfering RNA Proteins 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 101710040537 TNF Proteins 0.000 description 1
- 102100009534 TNF Human genes 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 102100016864 TYK2 Human genes 0.000 description 1
- 101700057652 TYK2 Proteins 0.000 description 1
- 102000015774 TYK2 Kinase Human genes 0.000 description 1
- 108010010057 TYK2 Kinase Proteins 0.000 description 1
- 229960001967 Tacrolimus Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N Tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 240000000280 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229960005032 Treprostinil Drugs 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N Trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000003298 Tumor Necrosis Factor Receptors Human genes 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 229960005080 Warfarin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000005035 acylthio group Chemical group 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical class 0.000 description 1
- 229960003692 aminobutyric acid Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001396 anti-anti-diuretic Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229960002890 beraprost Drugs 0.000 description 1
- 229940000635 beta-Alanine Drugs 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000037348 biosynthesis Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960003065 bosentan Drugs 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- QXJJQWWVWRCVQT-UHFFFAOYSA-K calcium;sodium;phosphate Chemical compound [Na+].[Ca+2].[O-]P([O-])([O-])=O QXJJQWWVWRCVQT-UHFFFAOYSA-K 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000001066 destructive Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- NPXWSRDMHQCNRM-UHFFFAOYSA-N ethyl 4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 NPXWSRDMHQCNRM-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000003260 fluorescence intensity Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 229940013945 gamma-Aminobutyric Acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 150000002344 gold compounds Chemical class 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 125000004996 haloaryloxy group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 1
- 229960002240 iloprost Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002101 lytic Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 201000007224 myeloproliferative neoplasm Diseases 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004999 nitroaryl group Chemical group 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 229940006093 opthalmologic coloring agents Diagnostic Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001184 polypeptide Chemical group 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229940094025 potassium bicarbonate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 229960002578 sitaxentan Drugs 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 125000004434 sulfur atoms Chemical group 0.000 description 1
- 230000003319 supportive Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004654 survival pathway Effects 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 1
- 229960003676 tenidap Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N trans-L-hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Abstract
A method of treating a subject presenting with multiple myeloma at a stage characterized by an increase in the prevalence of MM cells that (1) are IL-6 non-responsive and/or (2) have a CD45phenotype, comprising administering to the subject an amount of a compound of formula Ib.
Description
This invention relates to the enzyme Janus kinase 2, or JAK2, More particularly, the invention relates to the use of JAK2 inhibitors in the treatment of multiple myeloma and related myel oproli ferat î ve neop lasms.
Background to the Invention
Multiple myeloma (MM) is an incurable drug résistant clonal B cell malignant neoplasm localized to the bone marrow that is associated ultimately with overproduction of monoclonal antibody by plasma cells leading to destructive lytic bone lestons and end organ damage in the form of rénal and cardiac dysfonction. Current research is focused on agents that reduce activity of interlcukin-6 (IL-6) which is believed to play a central rôle in the pathogenesis of MM through its stimulation ofthe JAK/STAT pathway responsible for plasma cell growth and prolifération.
Some human myeloma cell lines (HMCL) cannot proliferate or survive without exogenous IL-6 [9, 10] and some conventional drugs are ineffective in the presence of 1L-6 [l I13]. The bone marrow niicroenvironmenl (BMME), known to provide supportive signais to MM cells, produces IL-6 [14] hence reducing the pro-survival effect of IL-6 may abrogate the drug résistant phenotype of MM.
JanLis-activated Kinases (JAKs) are well characterized signalling kinases comprising four family members JAKl, JAK2, JAK3 and TYK2 thaï are important in haematological malignancy as JAK mutations hâve been shown to contribute to the pathogenesis of both myeloproliferative disorders [l-3] and leukaemias [4]. JAKs hâve an established rôle in signalling for many cells [reviewed by 5], In MM, JAKs are activated by a variety of cytokines including interlukin-6 (IL-6) [6, 7], inlerferon-a [6, 8] and cpidermal growth factor [6]. Many pathways downstreain of JAKs are exploited by malignant cells.
A variety of JAK inhibitors hâve been developcd reccntly, and their utility as treatments ol’MM is being investigated. CYT387 is a novel JAK inhibitor that can inhibil JAKl, JAK2, JAK3 and TYK2 kinase activity [15, 16]. The structure and development ofthe compound has recently been described [17], Other JAK inhibitors currently in various stages of development and investigation include INCB000020 [18], 1NCB16562 [19], AG490 [20, 21], AZDI480 [22] and Pyrîdone 6 [23], as well as WP1066 [24]. Given lhe putative rôle of IL-6 in MM drug résistance JAK inhibitors are being investigated for their potential use as single agent or in combination therapy for MM. Furthermore, preliminary in vitro data has demonstrated the potential of JAK/STAT inhibition to sensitize MM cells to conventional thérapies [21],
-2Despite these efforts, MM remains an incurable disease, resulting annually in 11,000 deaths and affecting 16,000 additional sufferers each year. It would be useful to provide additional agents and methods for the treatment of subjects afflicted with this disease.
Summaryofthe Invention
It has now been found that CYT 387 is active in the treatment of multiple myeloma, and particularly in treating forms of MM in which the target MM cells are CD45- and/or are IL6 non-responsive. This effect of CYT 387 thus expands on the types of multiple myeloma that can be treated, relative to other agents that also exhibit JAK inhibition activity.
More particularly, and in one of its aspects, lhe présent invention provides for the use of CYT 387 to inhibit growth and/or prolifération, i.e., the viability, of MM cells having a CD45phcnotype. In addition, and in another of its aspects, the présent invention provides for the use of CYT387 to inhibit the growtli and/or prolifération, i.e., the viability, of MM cells that are considered IL-6 non-responsive. Compounds having a JAK kinase inhibition profile like that of CYT 387 are also useful in lhe présent method.
The activity ofCYT 387 allows for the treatment of MM at a later stage ofthe disease, when the MM cells shifl phenotypically from a CD45+ phenotype to a predominantly CD45plienotype, thereby allowing for prolongée! survival in patients desperate for treatment.
In a related aspect, the présent method comprises the step of assessing the subject or a biological sample obtained thcrelrom, identifying multiple myeloma subjects meeting at least one ofthe criteria noted above, and then treating tlie identified subjects with CYT387 or a related compound.
In another aspect ofthe présent invention, there is provided an article of manufacture, comprising CYT 387 or a related compound in combination with a label indicating treatment of a subject presenting with al least one of the noted criteria.
In a related aspect ofthe présent invention, there is provided a kit comprising CYT 387 or a related compound in combination with printed instruction teaching a method of selecting a subject for CYT387 or a related compound therapy based on the sélection criteria herein described.
These and other aspects and embodiments ofthe présent invention are now described in greater detail with reference to the accompanying drawings in which:
Reference to the Figures
Figure 1 : CYT387 prevents signalling downstream of IL-6 or coculture stimulation. HMCL were incubated with or without CYT387 (0,5 - 2 μΜ) for 1 hour before stimulation with 10 ng/nil IL-6 for 15 minutes. Cells were then harvested and p-STAT3 (pY705) was measured. (A) By intraccllular FACS with the géométrie mean fluorescence intensily measured and graphed (n = 3, mean ± SE, Slimulated cells ± CYT387 were analyzed )
-3 using a One-way ANOVA with Tukey post-test * = p <0.05, ** = p < 0.01,*** = p < 0.001). (B) By western blot for p-STAT3 (pY705), total STAT3 and α-tubulin as a loading control.(C) p-STAT3 was also induced in IIMCL using a direct cocullure (CC) with IIS5 immortalized bone marrow stromal cells or primary bone marrow stromal cells or a transwell (TW) “soluble only” CC with HS5. I IMCL were fluorescently labelled with CD38 or CD 138 and stimulated for 15 minutes with or without co-trealment with 2 μΜ CYT387. Représentative plots of NCIH929, (n = 3, for NCI-H929, OCI-MYl and U266). (D) NC1-H929, OCI-MYl and U266 cells were starved overnight and stimulated with 5 ng/ml IL-6 and lOOng/ml IGF-l for 15 minutes with or without co-lreatment with 2 μΜ CYT387. p-AKT (pS473) and p-ERKl/2 (pT202/pY204) were measured by intracellular FACS with the géométrie mean fluorescence intensity normalized to the untreated (UT) control and averaged (n = 4, mean ± SE. Stimulated cells ± CYT387 were analyzed using a One-way ANOVA with Tukey post-test * = p <0.05, ** = p < 0.01 ).
Figure 2: CYT387 inhibits I IMCL prolifération. (A) CYT387 inhibits IIMCL in a time and dose dépendent manner. IL-6 phenotype HMCL (ANBL-6, OCIMY1,U266 and XGI ) and non-IL-6 phenotype HMCL (LP-I, NCI-I1929, OPM2 and RPM1-8226) were cultured for 24, 48 and 72 hours UT, with CYT387 (0.1,0.5, 1,2.5 or 5 μΜ) or with vehicle (DMSO). Cell prolifération was then detennined by M I S Assay (72 liour data shown, n = 3, mean ± SE) (B) Treatment with CYT387 inhibits myeloma cell prolifération even in the presence of IL-6. Absolute cell numbers of viable cells were detennined by haemocylomcler counts of HMCL cultured alone (Untreated) with IL-6 (10 ng/ml) with CYT387 (0.5 - 1 μΜ) or with IL-6 and CYT387. Culture with CYT387 greally decreased the prolifération of lhe IIMCL over 72 hours (treatment at time 0 only). Results represent the mean of 3 independent experiments ± SE. (C) CYT387 prevents cell cycling. HMCL were treated with CYT387 (1 μΜ or 5 μΜ) for 24 and 72 hours then they were harvested and fixed and cell cycle analysed by FACS. Représentative cell cycle plots of Cil 1929 UT or 5 μΜ CYT387 for 24 or 72 hours, with mean of 4 independent experiments ± SE of cycling cells in G2/M phase of the cell cycle.
Figure 3: CYT387 induces apoplosis in IIMCL. (A) Représentative Annexin-V and Propidium Iodide (PI) plots of NCI-H929. UT, Vehicle (DMSO) treated, 24 hours 5 μΜ CYT387 treatment and 72 hours 5 μΜ CYT387 treatment. (B) Proportion of viable (AnnexinV- and PI-) cells after CYT387 treatment compared to UT. Data shown is the mean of 4 independent experiments ± SE.
Figure 4: CYT387 synergizes with melphalan and bortezomib in IIMCL. (A)
Dose effect curves of NCI-H929, OC’l-MYl and U266 after 24 and 48 hours treatment CYT387 treatment (0.5 - 10 μΜ) as determined by the proportion of PI+ cells minus background death (untreated). Meanof'4 independent experiments ± SE. (B) CYT387 in combination with melphalan or bortezomib show synergism. Synergy was measured using a combination index calculated by Calcusyn software, where values less than l represent synergism, plotted against the fraction of cells killed with various dose/ratios of the drugs. Syncrgy is seen between melphalan and CYT387 at a range of doses/ratios/cell lines and lime points. Bortezomib and
CYT387 demonstrated synergistic or nearly additive in 18/24 combinations. Synergism was calculated from dose effect curves of the mean of 4 independent experiments.
Figure 5: CYT387 induces apoplosis in primary samples as a single agent or in combination with melphalan and bortezomib. (A) Proportion of apoptotic (Apo 2.7+) CD38+CD45- primary patient myeloma cells after 48 hours CYT387 treatment (n = 6). (B) Synergy between CYT387 and melphalan or bortezomib after 24 hours treatment as determined by calcusyn software in primary patient CD38+CD45- cells.
Detailed Description of the Invention
CYT 387 is a phenylaminopyrimidine compound having CAS registration number CAS 1056634-68-4, the chemical name N-(cyaiioiiiethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4pyrimidinyl]-benzamide, and the structure shown below:
NH
CN
Synthesis, formulation and therapeutic use of CYT 387 is described in WO 2008/109943 published 18 September 2008; and in Blood, 2010, 115(25):5232-40. Of course, CYT387 can be used in the form of a sait, solvaté or prodrug if desired.
“Related compounds” are compounds related to CYT 387 by their sélective J AK inhibition signature, in which a préférence is shown for binding lo and inhibition of JAK2 and JAK.1, relative to JAK3 and other members of the kinase family, and by their structural conformance to thc formula:
Ib wherein
Z is independently selected from N and CH;
R1 is independently selected from 1 1, halogen, OH, CONFIR2, CON(R2)2, CF3, R2OR2,
CN, morpholino, thiomorpholinyl, thiomorpholino-l, I-dioxide, substituted or
-5unsubstitutcdpiperidinyl, substituted or unsubstitutedpiperazinyl, imidazolyl, substituted or unsubstitutedpyrrolidinyl and C|.4alkylene wherein the carbon atoms arc optionally replaced with NRY and/or O substituted with morpholino, thiomorpholinyl, thiomorpholino-l,l-dioxide, substituted or unsubstitutedpiperidinyl, substituted or unsubstitutedpiperazinyl, imidazolyl or substituted or unsubstitutedpyrrolidinyl;
R2 is substituted or unsubstituted C^alkyl;
RY is II or substituted or unsubstituted Cj.4alkyl;
RK is RXCN;
Rx is substituted or unsubstituted C^alkylene wherein up to 2 carbon atoms can be optionally replaced with CO, NSO2R1, NRY, CONRy, SO, SO2 or O;
R is l-I or CMalkyl, or an enantiomer thereof, a prodrug thereof or a phannaceutically acceptable sait thereof.
The term “Ci.4alkyl” refers to straight chain or branched chain hydrocarbon groups having from l to 4 carbon atoms. Examples include methyl, ethyl, propyl, ïsopropyl, butyl, isobutyl, sec-butyl, and tert-butyl.
The term “halogen” refers to fluorine, chlorine, bromine and iodine.
The term “substituted” refers to a group that is substituted with one or more groups selected from C|.4 alkyl, Cj.(lcycloalkyl, C2.(,alkenyl, C2.6alkynyl, C|.(,alkylaryl, aryl, heterocycylyl, halo, haloC|.6alkyl, haloCi.6cycioalkyl, haloC2.6alkenyl, haloC2.(,alkynyl, haloaryl, haloheterocycylyl, hydroxy, C|.6alkoxy, C2.(,alkenyloxy, C2.6alkynyloxy, aryloxy, heterocyciyloxy, carboxy, haloC|.6alkoxy, haloC2.6alkenyloxy, haloC2.6alkynyloxy, haloaryloxy, nitro, nitroCi_6,alkyl, nitroC2.6alkenyl, nitroaryl, nitroheterocyclyl, azido, amino, Ci.fcalkylamino, C2.ftaikenylamino, C2.6alkynylainino, arylamino, heterocyclamino acyl, C|. 6alkylacyl, C2.6alkcnylacyl, C2.(,alkynylacy], arylacyl, heterocycylylacyl, acylatnino, acyloxy, aklehydo, C|.f)alkylsulphonyl, arylsulphonyl, C[.6alkylsulphonylamino, arylsulphonylamino, C|. f,alkylsulphonyloxy, arylsulphonyloxy, Ci.(,aikylsulphenyl, C2.(,alklysulphenyl,arylsulphonyl, carboalkoxy, carboaryloxy, mercapto, C|.f,alkylthio, arylthio, acylthio, cyano and the like. Preferred substituents are selected from the group consisting of Cm alkyl, C^cycloalkyl, C2. (.alkenyl, C’2.(,alkynyl, Ct-oalkylaryl, aryl, heterocycylyl, halo, haloaryl, haloheterocycylyl, hydroxy. C|„ialkoxy, aryloxy, carboxy, amino, C|.(,alkyiacyl, arylacyl, heterocycylylacyl, acylamino, acyloxy, C|.(,alkylsulphenyl, arylsulphonyl and cyano.
The term “aryl refers to single, polynuclear, conjugated or fused residues of aromatic hydrocarbons. Examples include phenyl, biphenyl, terphenyl, quaterphcnyl, naphlhyl, tetrahydronaphtliyl, anthracenyl, dihydroanthracenyl, benzanlhracenyl, dibenxantliracenyl and phenanlhrcnyl.
The term “unsaturaled N-containing 5 or 6-membered hcterocyclyl” refers to unsaturaled, cyclic hydrocarbon groups containing al least one nitrogen. )
-6Suitable N-containing heterocyclîc groups include unsaturated 5 to 6-æembered heteromonocyclic groups containing l to 4 nitrogen atoms, for example, pyrrolyl, pyrrolinyi, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl or tetrazolyl; unsaturated 5 or 6-membered heteromonocyclic group containing l to 2 oxygen atoms and l to 3 nitrogen atoms, such as, oxazolyl, isoxazolyl or oxadiazolyl; and unsaturated 5 or 6-membered heteromonocyclic group containing l to 2 sulphur atoms and l to 3 nitrogen atoms, such as, thiazolyl or thiadiazolyl.
In preferred embodiments, compounds related to CYT 387 include those in which K1 is substituted in the para position by morpholinyl and in the orlho position by H, Z is carbon, and R11 is H, methyl or methoxy.
In particularly preferred embodiments, R8 is -C(O)-NH-CH2-CH^N; -C(O)-N11-C(C1 hhCHzN; or -NH-C(O)-CT13-CHzN.
Spécifie compounds related to CYT 387 useful in accordance with the présent method include:
/V-(cyanomethyl)-4-(2-(4-morpholinophenylammo)pyrimidin-4-yl)benzamide; /V-(cyanomcthyl)-3-(2-(4-morpholinophenyianiino)pyrimidin-4-yl)benzamide; (V-(cyanomethyl)-3-melhyl-4-(2-(4-mori)holinophenylamino)pyrimidin-4-yl)benzamide; /V-(cyanomethyl)-2-methyl-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide; 2-cyano-/V-(3-(2-(4-inorpholinophenylamino)pyrimidin-4-yl)benzyl)acetamide; 2-cyano4V-(3-(2-(4-morpholinophenylamino)pyrimidin-4-yl)phenyl)acetamide;
JV-(cyanomethyl )-4-(2-(3-morphol inophenylamino)pyri midi n-4-yl)benzamide; /V-(cyanomethyl)-4-(2-(4-thiomorpholinophenylamino)pyrimidm-4-yl)benzamide; and jV-(cyanomethyl)-4-(2-(4-(morpholinomethyl)phenylamino)pyrimidin-4-yl)benzamide.
In lhe présent invention, CYT 387 and related compounds are used to ireat multiple myeloma (MM) cells that hâve a CD45 négative (CD45-) phenotype, and/or MM cells that are considered IL-6 non-responsive. MM cells are the disease cells that form plasmacytomatumours that are the hallmark of multiple myeloma. “CD45- phenotype” refers to a MM cell that tests négative or dim, as distinct from intermediate to bright, for surface expression of the protein marker known as CD45, which is a well-known marker of ail hematopoietic cells. The CD45phenotype is also ascribed herein with reference to a population of MM cells in which the prevalence of CD45- cells within that population exceeds at least about 10% of that population, such as at least about 15%, or 20%, or 25%, or 30%, or 35%, or 40%, or 45% or al least about 50% of that population. Détection of CD45 on the cellular surface is readily achieved using fluorescence-labeled CD45 monoclonal antibody and established techniques of fluorescenceactivation cell sorting (FACS) or any related means for identifying cells that bind the CD45 antibody. Reference can be made for instance to the articles published by Moreau et al, q/'
-7Haematologica, 2004, 89(5):547, and by Kumar et al, Leukemia, 2005, 19:1466, the disclosures of which are incorporated herein by reference.
MM cells that are “IL-6 non-responsive” are identified as cells that do not rely for survival on the presence of interleukin-6 (IL-6). Thus, a MM cell that is IL-6 non-responsive shows insubstantial response, in ternis such as IL-6 receptor stimulation or downstream signalling events, when incubated with an otherwise stimuiatory amount of IL-6. Such MM cells can particularly include those MM cells that are résident in the bone marrow environment, and which thus grow in the same environment as bone marrow stromal cells, but they also include MM cells in circulation that are not exposed lo the marrow environment.
Within the realm of MM and its progression and development, CD45 represents an early marker of the disease MM cells. As the disease progresses, a shift occurs in CD45 phenotype of those cells, in which the prédominance of CD45+ cells wanes, and the population of disease plasma cells becomes predominantly CD45- (see Kumar et al, Leukemia, 2005, 19(8): 1466). A shift also occurs in the number of IL-6 non-responsive cells, with this cell form becoming prédominant in the later stages of disease.
In the présent method, the use of JAK inhibitors is proposed for the treatment of MM cells, and plasmacytomatumours that anse therefrom, that hâve acquired the CD45- and/or IL-6 non-responsive phenotype. The effect of JAK inhibition on this particular cell population is surprising, given that the JAK2 response to stimulation of the IL-6 receptor is believed to hâve a central and important rôle in progression of MM. Even when this IL-6 pathway is not involved in MM disease progression, CYT 387 fonctions to inhibit the growth and/or prolifération of these cells.
“Related disorders” are disorders related to MM as plasma cell disorders characterized by a clonal population of hematopoietic B cells that produce a monoclonal protein (M protein, or paraprotein). The clinical manifestations of these disorders resuit from lhe uncontrolled and progressive prolifération of a plasma cell clone, the effect of normal bone marrow replacement, and the overproduction of monoclonal proteins. MM is a plasma cell dyscrasia and includes newly diagnosed as well as relapsed MM.
Subjects, most notably human patients, who présent with MM are identifiable using any of the established diagnostic criteria and staging parameters. These include criteria established by the International Myeloma Workshop which distinguishes symptomatie MM subjects from those having asymptoinalic MM or gammopathy of undetermined significance (MGUS), by lhe presence of M protein in sérum or urine, clonal bone marrow plasmacytosis or plasmacytoma and related organ and tissue impairment. For staging of MM, the guidelines proposed by the Soulhwesl Oncology Group (SWOG) can be used, which rely essentially on measurements of B2-miciOglobulin and lhe relative presence of sérum albumin, with >5.5mg/L β2-Μ and <3.0g/dL indicaling stage IV disease. Ollier useful guidelines bave been established using the c-Z
-8Duire and Salmon staging system (using hemoglobin, sérum calcium, radiography and M protein).
In the présent method, subjects selected for treatment are those presenting with MM that also display an increase in the presence of CD45- cells within the population of MM cells. The increase in the presence of the CD45- cells is seen in subjects having newly diagnosed or relapsed MM, relative to subjects afflicted with smoldering MM or MGUS. Subjects having a relatively dramatic increase in the prevalence of CD45- MM cells particularly include those MM subjects diagnosed with stage III or stage IV ofthe disease. In a preferred embodiment, the number of CD45- cells within the population is at least 10% ofthe total population, such as 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or more ofthe total MM cell population. Thus, in a représentative sample of 100 MM cells extracted from the subject, the patient population targeted for treatment by the présent method includes those presenting with a MM cell population in which 10-50% or more of the MM cells test négative for the CD45 marker.
In the présent method, subjects diagnosed with MM can first be screened lo select those subjects presenting with a MM cell population in which the CD45- phenotype is increased relative lo subjects afflicted with early stages of the disease, such as the smoldering MM stage. Screening is achieved using a MM cell population extracted from the subject, and then assaying the population such as by CD45 MAb-based flow cytometry to identify subjects in which there is an increase in CD45- MM cells. The MM cell population can also be assessed to reveal the prevalence of IL-6 non-responsive cells, the presence of which indicates the subject is a candidate for treatment by the présent method.
For use in the présent method, CYT 387 or a related compound is formulated according to standard pharmaceutical practice.
The compounds may be prepared as salts which are pharmaceutically acceptable, such as salts of pharmaceutically acceptable calions such as sodium, potassium, lithium, calcium, magnésium, ammonium and alkylammonium; acid addition salts of pharmaceutically acceptable inorganic acids such as hydrochloric, orthophosphoric, sulfuric, phosphoric, nitric, carbonic, boric, sulfamic and hydrobromic acids; or salts of pharmaceutically acceptable organic acids such as acetic, propionic, butyric, tartaric, maleic, hydroxymaleic, fumaric, cilric, lactic, mucic, gluconic, benzoic, succinic, oxalic, phenylacctic, methancsulfonic, trihalomethanesulfonic, toluenesulfonic, benzenesulIonic, iscthionic, salicylic, sulphanilic, aspartic, glutamic, edetic, stearic, palmitic, oleic, lauric, pantothenic, tannic, ascorbic, valeric and orotic acids. Salts of amine groups may also comprise quatemary ammonium salis in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl oraralkyl moiety.
Where a compound possesses a chiral center Lhe compound can be used as a purified enantiomer or diastereomer, or as a mixture of any ratio of stereoisomers. It is however -D preferred that the mixture comprises at least 70%, 80%, 90%, 95%, 97.5% or 99% of the preferred isomer, where the preferred isomer gives the desired level of potency and selectivity.
Prodrugs of the compounds of formula Ib can also be administered. For example, compounds of formula Ib having free amino, amido, hydroxy or carboxylic acid groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues which are covalently joined through peptide bonds to free amino, hydroxy and carboxylic acid groups of compounds of the invention. The amino acid residues include the 20 naturally occurring amino acids coinmonly designated by three letter symbole and also include, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-mcthylhistidine, norvlin, beta-alanine, gammaaminobutyric acid, citrulline, homocystéine, hoinoserine, omithine and methioinesulfone. Prodrugs also include compounds wherein carbonates, carbamates, amides and alkyl esters which are covalently bonded to the above substituents of compounds of the présent invention through the carbonyl carbon prodrugsidechain. Prodrugs also include phosphate dérivatives of compounds (such as acids, salts of acids, or esters) joined through a phosphorus-oxygen bond to a free hydroxyl of compounds of formula Ib, Prodrugs may also include N-oxides, and S-oxides of appropriate nitrogen and sulfur atoms in formula Ib.
The compound may be administered as a pharmaceutical composition comprising at least one of lhe compounds of the formula Ib and a pharmaceutically acceptable carrier. The carrier must be pharmaceutically acceptable means that it is compatible with lhe other ingrédients of the composition and is not dclelerious to a subject. The compositions may contain other therapeutic agents as described below, and may be formulated, for examplc, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (for example, excipients, binders, preservatives, stabilizers, flavours, etc.) according to techniques such as those well known in the art of pharmaceutical formulation (See, for example, Remington: The Science and Practice of Pharmacy, 2lst Ed., 2005, Lippincott Williams & Wilkins).
The compound may be administered by any suitable means, for examplc, orally, such as in the form of tablets, capsules, granules or powders; sublingually; buccally; parenterally, such as by subeutaneous, intravenous, intramuscular, intra(trans)dermal, or intracisternal injection or infusion techniques (e.g., as stérile injectable aqueous or non-aqueous solutions or suspensions); nasally such as by inhalation spray or insufflation; topically, such as in the form of a cream or ointment ocularly in the form of a solution or suspension; vaginally in the form of pessaries, tampons or creams; or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents. The compounds may, for example, be administered in a form suitable for immédiate release or extended release. Immédiate release or extended release may be achieved by the use of suitable pharmaceutical c*
- lOcompositions comprising lhe compounds, or, particularly in lhe case ol'extended release, by lhe use of devices such as subcutaneous implants or osmolic pumps.
The pharmaceutical compositions for the administration may conveniently be presented in dosage unit form and may be prepared by any of lhe methods well known in (lie art of pharmacy. These methods generally include the step of bringing lhe compound of formula lb into association with the carrier which conslitutes one or more accessory ingrédients. In general, the pharmaceutical compositions are prepared by uiiiformly and intimately bringing lhe compound into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In lhe pharmaceutical composition the active object compound is included in an amount sufficient lo produce the desired effect upon the process or condition of diseases. As used herein, the term composition is intended to encompass a product comprising the specified ingrédients in (lie specified amounts, as well as any product which results, directly or indirectly, from combination ofthe specified ingrédients in the specified amounts.
The pharmaceutical compositions may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, émulsions, hard or soil capsules, or syrups or élixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents such as sweetcning agents, flavouring agents, colouring agents and preserving agents, e.g. lo provide pharmaceutically stable and palatable préparations. Tablets contain the compound of formula lb in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulaling and disinlegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnésium stéarate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in lhe gastrointestinal tract and thereby provide a suslained action over a longer period. For example, a lime delay material such as glycerylmonoslearate or glyceryldistearate may bc employed. They may also be coated to form osmolic therapeutic tablets for control release.
Formulations for oral use may also be presented as hard gelatin capsules wherein lhe compound of formula lb is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the compound of formula lb is mixed with water or an oil medium, for cxample peanul oil, liquid paraffin, or olive oil,
Aqueous suspensions contain lhe active materials in admixture with excipients suitable for lhe manufacture of aqueous suspensions. Such excipients are sitspending agents, for J
- Il example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for cxample poiyoxyethylene stéarate, or condensation products of ethylene oxide with long chain aliphalic alcohols, for example heptadecaethyleneoxycelanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as poiyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitanmonooleate. The aqueous suspensions may also contain one or more préservât ives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
Oily suspensions may be formulated by suspending the compound of formula lb in a vegetable oil, for example arachîs oil, olive oil, sesame oil or coconut oil, or in a minerai oil such as liquid paraffin. The oily suspensions may contain a thickcning agent, for example beeswax, hard paraffin orcetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral préparation. These compositions may be preserved by the addition ofan anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for préparation ofan aqueous suspension by the addition of water provide the compound in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be présent.
l he pharmaceutical compositions may also be in the form of oil-in-water émulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a minerai oil, l'or example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturallyoccurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy beau, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitanmonooleate, and condensation products ofthe said partial esters with ethylene oxide, for example polyoxyethylenesorbitanmonooleate. The émulsions may also contain sweetening and flavoring agents.
Syrups and élixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcenl, a preservative and flavoring and coloring agents.
The pharmaceutical compositions may be in the form of a stérile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which hâve been mentioned p/
- 12 above. The stérile injectable préparation may also be a stérile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in l ,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonie sodium chloride solution. In addition, stérile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the préparation of injectable formulations.
For administration to the respiratory tract, including intranasal administration, the active compound may be administered by any ofthe methods and formulations employed in the art for administration to the respiratory tract.
Thus in general the active compound may be administered in the form of a solution or a suspension or as a dry powder.
Solutions and suspensions will generally be aqueous, for example prepared from water alone (for example stérile or pyrogen-free water) or water and a physiologically acceptable cosolvent (for example éthanol, propylene glycol or polyethylene glycols such as PEG 400).
Such solutions or suspensions may additionally contain other excipients for example preservatives (such as benzalkonium chloride), solubilizing agents/surfaclants such as polysorbates (eg. Tween 80, Span 80, benzalkonium chloride), bnffering agents, isotonicityadjusting agents (for example sodium chloride), absorption enhancers and viseosity enhancers. Suspensions may additionally contain suspending agents (for example microcrystalline cellulose and carboxymethyl cellulose sodium).
Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray. The formulations may be provided in single or multidose form. In the latter case a means of dose metering is desirably provided. In lhe case of a dropper or pipette this may be achieved by the subject administering an appropriate, predetennined volume ofthe solution or suspension. In the case of a spray this may be achieved for example by means of a metering atomising spray pump.
Administration to the respiratory tract may also be achieved by means of an aérosol formulation in which the compound is provided in a pressurized pack with a suitable propcllant, such as a chlorofluorocarbon (CFC), for example dichlorodifluororncthane, trichlorofluoromethane or dichlorotetrafluoroethane, carbon dioxide or other suitable gas. The aérosol may conveniently also contain a surfactant such as lecilhin. The dose of active compound may be controlled by provision of a metered valve.
Alternatively lhe active compound may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch dérivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine ( P VP). Conveniently lhe powder carrier will form a gel in the nasal cavity. The powder composition j
- 13may be presented in unit dose form, for example in capsules or cartridges of eg. gelatin, or blister packs from which the powder may be administered by means of an inhaler.
In formulations intended for administration to the respiratory iract, including intranasal formulations, the active compound will generally have a small particle size, for example ofthe order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronisation.
When desired, formulations adapted to give sustained release ofthe active compound may be employed.
The active compound may be administered by oral inhalation as a free-flow powder via 10 a “Diskhaler” (trade mark of Glaxo Ciroup Ltd) or a mcter dose aérosol inhaler.
The compound may also be administered in the form of suppositories for rectal administration ofthe drug. These compositions can be prepared by mixing lhe drug with a suitable non-irritating excipient which is solid at ordinary températures but liquid at the rectal température and will therefore melt in lhe rectum to release the drug. Such materials are cocoa 15 butter and polyethylene glycols.
Compositions suitable for vaginal administration may be presented as pessarîes, tampons, crearns, gels, pastes, foams or sprays containing in addition to the active ingrédient such carriers as are known in the art to be appropriate.
For topical use, crearns, ointments, jellies, solutions or suspensions, etc., containing the 20 compound are employed. For purposes of this application, topical application can include mouthwashes and gargles.
For application to the eye, the active compound may be in the form of a solution or suspension in a suitable stérile aqueous or non-aqueous vehicle. Additives, for instance buffers, preservatives including bactericidal and fungicidal agents, such as phenyl mercurîc acetate or
5 nitrate, benzalkonium chloride, or chlorohexidine and thickening agents such as hypromellose may also be included.
Thecompound can also be administered in the form ofliposonies. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multilamellar hydrated liquid crystals that are dispersed in an aqueous 30 medium. Any non-toxic, physiologically acceptable and mclabolisable lipid capable of forming liposomes can be used. The présent compositions in liposome form can contain, in addition to a compound ofthe présent invention, stabilizers, preservatives, excipients and the like. The preferred lipids are the phospholipids and pliosphatidylcholines, both natural and synthetic. Methods to form liposomes are known in the art.
5 The compound may also be presented for use in the form of velerinary compositions, which may be prepared, for example, by methods that are conventional in the art. Examples of such veterinary compositions include those adapted for: d (a) oral administration, external application, for example drenches (e.g. aqueous or non-aqueous solutions or suspensions); ta blets or bol uses; powders, granules or pellets for admixture with feed stuffs; pastes for application to the longue;
(b) parentéral administration for example by subculaneous, intramuscular or intravenous injection, e.g. as a stérile solution or suspension; or (when appropriate) by intramammary injection where a suspension or solution is introduced in the udder via the teat;
(c) topical applications, e.g. as a cream, ointment or spray applied lo lhe skin; or (d) reclally or intravaginally, e.g. as a pessary, cream or foam.
The pharmaceutical composition may further comprise other therapcutically active compounds as noted herein which are usually applied in the treatment of the above mentioned pathological conditions. Sélection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prévention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.
Examples of other therapeutic agents include the following: endothelin receptor antagonists (egambrisentan, bosentan, sitaxsentan), PDE-V inhibitors (eg sildenafil, tadalafil, vardcnafil), Calcium channel blockers (eg ainlodipine, felodipine, varepamil, diltiazem, menthol), prostacyclin, treprostinil, iloprost, beraprost. nitric oxide, oxygen, heparin, warfarin, diuretics, digoxin, cyclosporins (e.g., cyclosporin A), CTLA4 lg. antîbodies such as ICAM 3, anti-IL 2 receptor (Anti Tac), anti CD45RB, anti CD2, anti CD3 (OKT 3), anti CD4, anti CDSO, anti CD86, agents blocking the interaction between C’D40 and gp39, such as antîbodies spécifie forCD40 and/or gp39 (i.e., CDI54), fusion proteins construcled fromCIMO and gp39(CD40lg and CD8gp39), inhibitors, such as nuclear translocation inhibitors, of NE kappa B function, such as deoxyspergualin (DSG), cholestérol biosynthesis inhibitors such as ÎIMG CoA reductase inhibitors (lovastalin and simvastatin), non-steroidal anti-inflammatory drugs (NSAlDs) such as ibuproten, aspirin, acetaminophcn, leflunomidc, deoxyspergualin, cyclooxygenase inhibitors such as celecoxib, steroids such as prednisoione or dexamethasone. gold compounds, beta-agonists such as salbutamol, LABA's such as salmeterol, leukotriene antagonists such as montelukast, antiproliférative agents such as methotrexate, EK.506 (tacrolimus, Prograf), inycophenolatemofetil, cylotoxic drugs such as azathioprine, VP-16, etoposide, fludarabine, doxorubin, adriamycin, amsacrinc, camptothecin, cytarabine, gemcitabine, fiuorodeoxyuridine, melphalan and cyclophosphamide, antimetabolites such as methotrexate, topoisomerase inhibitors such as camptothecin, DNA alkylators such as cisplatin, kinase inhibitors such as sorafenib, microtubule poisons such as paclitaxel, TNF-a inhibitors
- 15 such as tenidap, anti-TNF antibodies or soluble TNF receptor, hydroxy urea and rapamycin (sirolimus or Rapamune) or dérivatives thereof.
In one embodiment, MM subjects are treated with a combination of CYT 387 or a related compound, and melphalan.
In another embodiment, MM subjects are treated with a combination of CYT 387 or a related compound, and borlezomib.
When other therapeutic agents are employed in combination with the compounds ofthe présent invention they may be used for example in amounts as noted in the Physician Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art.
In a preferred embodiment, the présent method utilizes CYT 387 in combination with a compound selected from melphalan and borlezomib.
The présent invention also provides both an article of manu facture and a kit, comprising a container comprising CYT387 or a related compound in an amount effective to treat MM. The container may be simply a bottle comprising the compound in oral dosage form. each dosage form comprising a unît dose ofthe compound, in an amount for instance from about 50mg to 400mg, such as 200mg or 3()0mg. The kit will further comprise prînted instructions teaching the présent method of selecting subjects for treatment. The article of manufacture will comprise a label or the like, indicating treatment of a subject according to the présent method of patient sélection.
Generally, the term treatment means affecting a subject, tissue or cell to obtain a desired pharmacological and/or physiologiesI effect and include: (a) preventing the disease from occurring in a subject that may be predisposed to the disease, but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresling its development; or (c) relieving or ameliorating the effects of the disease, i.e., cause régression of tlie effects of lhe disease. In one embodiment, treatment achieves the resuit of reducing the number of CD45- and/or IL-6 non-responsive MM cells in the récipient subject.
The term subject refers to any animal having a disease which requires treatment by lhe présent method. In addition to primates, such as humans. a variety of other mammals can be treated using lhe methods of lhe présent invention. For instance, mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species can be treated. Dogs in particular are known to expérience multiple myeloma.
The terni “administering should be underslood to mean providing a compound ofthe invention to a subject in need of treatment.
The term therapeutically effective amount refers to lhe amount ofthe compound that will elicit lhe biological or medical response of a tissue, system, animal or human that is being soughl by the researcher, veterinarian, medical doctor or other clinician. _/
- 16 In the treatment or prévention of multiple myeloma, an appropriate compound dosage level will generally be about 0.01 to 500 mg per kg patient body weight per day which can be administered in single or multiple doses. Preferably, the dosage level will be about 0.1 to about 250 mg/kg per day; more preferably aboui 0.5 to about 100 mg/kg per day. A suitable dosage level may be about 0.01 to 250 mg/kg per day, about 0.05 to 100 mg/kg per day, or about 0.1 to 50 mg/kg per day. Within this range the dosage may be 0.05 to 0.5, 0.5 to 5 or 5 to 50 mg/kg per day. For oral administration, the compositions are preferably provided in the form of tablets containing l .0 to 1000 milligrams ofthe active ingrédient, particularly l .0,5,0, 10.0, I5.0. 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0. 250.0, 300.0,400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams ofthe active ingrédient. The dosage may bc selected, for example to any dose within any ofthese ranges, for therapeutic efficacy and/or symptomatic adjustment ofthe dosage to the patient to be treated. The compound will preferably be administered on a regimen of l to 4 times per day. preferably once or twice per day.
Il will be understood that the spécifie dose level and frequency of dosage for any particular patient may be variée! and will dépend upon a variety of factors including the activity of the spécifie compound employed. the metabolîc stability and length of action of that compound, the âge, body weight, general health, sex, diet, mode and time of administration, rate ofexcrétion, drug combination, the severity ofthe particular condition, and the host undergoing therapy.
In order to exemplify the nature ofthe présent invention such that it may be more clearly understood, the following non-limiting examples are provided.
Ail publications mentioned in this spécification are herein incorporated by reference. Il will be appreciated by persons skilled in the art thaï numerous variations and/or modifications may be made to the invention as shown in the spécifie embodiments without departing from the spirit or scope ofthe invention as broadly described. The présent embodiments are, therefore, to be considered in ail respects as illustrative and not restrictive.
Examples
CYT387 is an inhibitor of the kinase enzymes JAKl and JAK2, which have been implicated in a family of hcmatological conditions known as myeloproliferative neoplasms, including myclofibrosis. and as well in numerous disorders including indications in hcmalology, oncology and inflammatory discases. Myclofibrosis is a chronic debilitating disease in which a patient's bone marrow is replaçai by scar tissue and for which treatment options arc limited or unsatisfactory.
Synthesis ofCYT 387
Λ mixture of 4-cthoxycarbonylphenyl boronic acid (23.1 I g, 119 mmol), 2,4dichloropyrimidine (16.90 g, I I3 mmol), toluene (230 mL) and aqueous sodium carbonate (2
- 17M, 56 mL) was stirred vigorously and nitrogen was bubbled through the suspension for 15 minutes. Tetrakis(lriphenylphosphine)palladium[0] (2.61 g, 2.26 mmol) was added. Nitrogen was bubbled through for another 10 min., the mixture was heated to !00.°C, then at 75°C overnight. The mixture was cooled, diluted with ethyl acetate (200 mL), water ( 100 mL) was added and lhe layers were separated. The aqueous layer was extracted with ethyl acetate (100 ml) and the two organic extracts were combined. The organics were washed with brine, filtered through sodium sulfate, concentrated, and the résultant solid was triturated with methanol (10Ü mL) and filtered. The solids were washed with methanol (2x30 mL) and air dried. This material was dissolved in acetonitrile (150 mL) and dichloromethane (200 inL), stirred with MP.TMT Pd-scavenging resin (Agronaut part number 800471) (7.5 g) over 2 days. The solution was filtered, the solids were washed with dichloromethane (2x100 mL), and lhe filtrate concentrated to give ethyl 4-(2-chloropyrimidin-4-yl)benzoate as an off-white solid (17.73 g, 60%)— additional washing with dichloromethane yielded a further 1.38 g and 0.5 g of product.
Λ mixture of ethyl 4-(2-chloropyrimidin-4-yl)benzoate (26.15 g, 99.7 mmol) and 4inorpholinoaniline (23.10 g, 129.6 mmol) was suspended in 1,4-dioxane (250 mL). pToluenesulfonic acid monohydrate ( I 7.07 g, 89.73 mmol) was added. The mixture was heated at reilux for 40 h., cooled to ambienl température, concentrated then the residue was partitioned between ethyl acetate and 1:1 saturated sodium bicarbonale/water ( I L total). The organic phase was washed with water (2x100 mL) and concentrated. The aqueous phase was extracted with dichloromethane (3x200 mL). The material which precipitated during this workup was collected by filtration and set aside. The liquid organics were combined, concentrated, triturated with methanol (200 mL) and filtered to yield additional yellow solid. The solids were combined, suspended in methanol (500 mL), allowed to stand overnight then sonicatcd and filtered. The solids were washed with methanol (2x50 mL) lo give, after drying, ethyl 4-(2-(4niorphonlinophenylamino)pyrimidin-4-yl)benzoate (35.39 g, 88%).
A solution of ethyl 4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzoate (35.39 g, 87.6 mmol) in 3:1 methanol/leirahydrofuran (350 mL) was treated with lithium hydroxide (4.41 g, 183.9 mmol) in water (90 mL). l he mixture was heated ai reflux for 2 h., cooled, concentrated and acidified with hydrochloric acid (2M, 92.5 ntL, 185 mmol). The dark precipitate was filtered, washed with water, and dried under vacuum, l he solid was ground to a powder with a mortar and pestle, triturated with methanol (500 mL) then filtered again lo yield 4-(2-(4-morpholinophenylamino)pyrirnidin-4-yl)benzoic acid as a muddy solid. This material was washed with ether, air dried overnight, and ground to a fine powder with mortar and pestle. On lhe basis of mass recovery (34.49 g) the yield was assumed to be quantitative.
To a suspension of 4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)bcnzoic acid (lheorelically 32.59 g, 86.6 mmol) in DMF (400 mL) was added triethylamine (72.4 mL, 519.6 mmol, 6 eq.) The mixture was sonicaled to ensure dissolution. Ammoacetonitrile hydrochloride af
-18 (16.02 g, 173.2 mmol) was added followed by N-hydroxybenzotriazole (anhydrous, 14.04 g, 103.8 mmol) and 1 -ethyl-3-(dimelhylaminopropyl)carbodiÎmide hydrochloride (19.92 g, 103.8 mmol). The suspension was stirred vigorously overnight. The solvent was evaporated under reduced pressure, lhe residue was diluted with 5% sodium bicarbonate (400 mL) and water (300 mL), giving a yellow solid, which was broken up and filtered. The solids were washed several times with 100 mL portions of water, triturated with bot melhanol/dichloromethane (500 mL, 1:1), concentrated to a volume of approximately 300 mL), cooled and filtered. The solids were washed with cold methanol (3x100 mL), ether (200 mL) and hexane (200 mL) prior to drying to afford CYT 387 (31.69 g, 88%). M.p. 238-243°C.
Synthesis of related compounds is described by Bunis et al, in Bioorganic & Médicinal Chemistry Letters, 2009, 19:5887 and in W02008/109943, both disclosures being incorporated herein by reference.
MATERIALS AND METHODS
Rcagenls
The JAK.1/2 inhibitor CYT387 was dissolved in DMSO. The protéasome inhibitor bortezomib (Jansscn-Cilag) was reconslituted in saline. The alkylating agent melphalan (Sigma) was dissolved in 0.5% HCl.EtOH. Ail stock drug solutions were diluted in complété RI’MI1640 culture medium to various concentrations for expérimentation.
Cell Lines and Culture conditions
HMCL LP-1, NCI-11929, OPM2, RPMI-8226 and U266 and the human stromal cell line HS5 were obtained from the American Type Culture Collection, USA. ANBL6, 0CI-MY1 and XG-1 were a ktnd gift from the Winthrop P Rockefeller Cancer Institute, Arkansas. HMCL were grown and treated at densifies between 2.0 and 5.0 x 105 cell/ml in RPMI-1640 media (Gibco, Invitrogen) supplemented with 10% heat inaclivaled foetal bovine sérum (FBS, Lonza) and 2 mMLglutaminc (Gibco, Invitrogen). IL-6 dépendent cells lines were cultured with 2-5 ng/tnl IL-6 as required. Ail cells were cultured in a humidified ïncubator at 37°C with 5% CO2. Al! HMCL were passaged 24 hours prior to experimental set-up to ensure high viability and cycling.
Primary Samples
Primary MM samples were obtained from Bone Marrow Aspirâtes from relapsed and refractory MM patients following written informer! consent with approval from lhe Alfred Hospital Research and Elhics Committee and isolated and treated as previously described [25], Briefly, bouc marrow mononuclear cells (BMMC) were isolated with Ficoll-Paque Plus (Amersham Biosciences), washed in PBS and red blood cells were lysed with NH4CI solution (8.29 g/L ammonium chloride, 0.037 g/L EDTA, 1 g/L potassium bicarbonate). Cells were then washed again in PBS and quanlilated by haemocylometer. BMMC samples were then cultured
- 19in complété RPMI-l 640 media (as above for HMCL) for 24 hours. Subsequently the BMMC were plated at 5 x 105 cells/ml and were treated with CYT387 (5 - 50 pM) alone or (dépendant on cell numbers) in combination with bortezomib (5 - 40 nM) or melphalan (50 - 200 pM) for 24 and/or 48 hours. Drug-induced MM spécifie cell apoptosis was then compared to untreated and vehicle controls by staining for CD45 FITC (BD), CD38 PerCP-Cy5.5 (BD) and Apo 2.7 PE (Immunotech) to détermine apoptosis in CD45-CD38+ MM cells. Samples were subsequently analyzed by FACS. Primary bone marrow stromal cells (BMSC) were also collected from patient BMMC, cells that adhered to the flask after an initial 24 hour culture were cullured with conlinued sélection for adhèrent cells over several passages. Once cells had expandcd in culture they were used in coculture (CC) to stimulatc MM cells in parallel to experiments utilising the HS5 stromal cell line.
Western Blots (WB)
HMCL were treated with CYT387 (1 or 2 pM) for 60 minutes and then stimulated with ng/inl IL-6 for 15 minutes. Protein lysâtes of CYT387 treated and untreated HMCL were made with RIPA Buffer (50 mMTrîs.HCI pH 7.4. 150 mMNaCl, ! mM PMSF, 1 mM EDTA, 5 pg/ml Aprotiuin, 5 pg/ml Leupeptin, 1% Triton X-100, 1% Sodium deoxycholate and 0.1% SDS). Brielly cells were incubated in RIPA buffer on ice for 30-60 minutes before being cenlrifugcd ai 16,100 x g for 20 minutes at 4°C and the supematant collected. Protein concentration was quanti lied using DC Protein Assay (Bio- Rad) as per manufacturées instructions. Subsequently, 100 pg of each protein lysate was separated by 10% SDS-PAGE and blotled onto nitrocellulose (Hybond ECL, Amersham) using the Bio-Rad semi-dry transfer system. Membranes wereblocked with 5% skim milk powder 0.1% Tween-20/PBS for 60 minutes then incubated with mouse monoclonal antiphospho-STAT3 (pY705, Santa Cruz), mouse monoclonal anti-STAT3 (Santa Cruz) or mouse monoclonal anti-a-tubulin (Sigma25 Aldrich) for 1-2 hours at room température or overnight at 4°C. The blots were washed three times for 15 minutes in 0.1% Twecn-20/PBS, then incubated with secondary HRP tagged antibody (swinc anli-rabbit Ig MRP (Dako) or rabbit anti-mouse lg HRP (Dako)) for 1-2 hours at room température before washing as above. Blots were visitaiized with Supersignal west pico ECL reagents (Pierce).
Intracellular FACS
Activation of the JAK/STAT, P13K/AKT and Ras/MAPK pathways was investigated using intracellular flow cytometry to measure the phosphorylation of STAT3 at tyrosine 705 (pSTAT3), AKT at serine 473 (p-AKT) and ERK.1/2 at threonine 202 and tyrosine 204 (p-ERK). HMCL were stimulated alone with 10 ng/ml IL-6 ± 200 ng/ml IGF-I or stimulated in CC with
HS5 stromal cells or primary BMSC with or without CYT387 treatment. For CC HS5 and primary BMSC were seeded into a 24 well plate at 2 x 105 cells/ml and allowed lo establish for J
-204 hours, aller which HMCL prestained with CD38 or CD138 F1TC (BD) were added. MM cells were stimulated alone ( 10 ng/ml IL-6 or 5 ng/ml lL-6 and 100 ng/ml IGF-1 ), or in CC (direct CC with stroma or transwell (TW) CC with stroma) with or without either 60 minutes of CYT387 prelreatmcnt or 15 minutes CYT387 co-treatment. After stimulation ± treatment, MM cells were harvested and fixed with 2% paraformaldéhyde for 10 - 30 minutes, washed then permeabilised with methanol overnight. Methanol was washed off and the cells were resuspended in p-STAT3 PE (BD), p-AKT PE (BD) or p-ERK (BD) and stained for 45 - 60 minutes at room température. Unbound antibody was washed off and the cells resuspended in 2% FBS PBS and acquired by FACS.
Prolifération and Viability Assays
The viability and prolifération of CYT387 treated HMCL and untreated/vehicle controls were determined using various methods as described previously [26]. Prolifération was measured first using Cellliter 96 AQeous one solution cell prolifération assay MTS reagent (Proniega) on a panel of 8 HMCL. Cells were cultured at 2.0 * 105 cell/ml in 100 μΐ fresh media in 96 well plates for 24, 48 and 72 hours with CYT387 (0.1 - 5 μΜ). 20 μ! of MTS reagent was added for the final 4 hours of treatment and the plates were read at 490 nm using a Fluostar Optima plate reader (BMG Labtech). The viable cell numbers of a panel of 5 HMCL that were treated with CYT387 with and without IL-6 co-treatment was also measured by trypan blue staining and haemocytomcter count. The HMCL NCI-H929, OC1-MY1 and U266 were then selected for further analysis. Apoptosis of CYT387 treated cells was assessed by FACS with Annexin-V and propidium iodide (PI) staining. HMCLs were treated for 24 or 72 hours with 1 or 5 μΜ CYT387 then harvested and washed in Annexin Buffer (0.01 HEPES, 0.14 M NaCI, 2.5 mM CaC12, pl i 7.4) and stained with Annexin-V FITC (Biosource) made up in Annexin Buffer for 30 minutes at room température. Unbound antibody was then washed off with Annexin Buffer and cells were resuspended in Annexin Bufler with 62.5 ng/ml PI (SigmaAldrich) and analyzed by FACS.
For the synergy experiments HMCL were treated with CYT3S7 in combination with bortezomib or melphalan for 24 and 48 hours before being harvested and resuspended in FACS Buffer (0.5% III FBS in PBS) supplemented with 62.5 ng/ml PI (Sigma-Aldrich). Cells were iinmediately analyscd by FACS. The proportion of PI positive cells was quantitated by subtracting lhe background death of unlreated cells. Single drug treated cells were compared to combination treated cells and synergism was calculated using Calcusyn software (Biosoft).
Cell Cvcling
The effect of CYT387 treatment on HMCL cell cycling was measured aller 24 and 72 hours. CYT387 (I or 5 μΜ) treated and untreated HMCL were harvested, washed in PBS and resuspended in 100 μΙ PBS. Cells were fixed with I ml of cold 70% éthanol while being o/
-2l vortexed. Tubes were stored at -20°C until analysis. Once all samples were collected tubes were centrifuged at 500 x g for 10 minutes, the supematant was carefully removed and the cells washed in 5 ntl PBS. After Lhe final wash cells were resuspended 250 - 500 pl of Pl/RNase staining buffer (BD) and incubated in the dark at room température for 15 minutes before being analyzed by FACS.
Data Analysis
All FACS data was acquired on a BD FACScalibur and data analysis done using Flowjo 7.6 Software (Treestar, USA). Ail statistical analysis was done using GraphPad Prism 5.03 software (USA).
RESULTS
JAK/STAT signal]mg is inhibited by CYT387 IL-6 signalling through the JAK/STAT palhway is well characterized in MM cells with binding of IL-6 to its receptor inducing JAK2 to phospliorylate STAT3. The ability of CYT387 to inhibit JAK2 was first confirmed by measuring the level of STAT3 phosphorylation by western blolting and FACS. FIMCL (NClH929, OCl-MYl and U266) were incubated with CYT387 for I hour before being stimulaled with IL-6 for 15 minutes to induce p-STAT3. CYT387 (0.5 - 2 pM) inhibited the phosphorylation of STAT3 in IL-6 stimulated samples as demonstraled by FACS (Figure l A) and confirmed by western blolting (Figure l B). Total STAT3 protein was unaffected.
Given the importance ofthe BMME in MM growth and survival it was important to establish if CYT387 could similarly modulate signalling in MM cells in CC with BMSC. This was done with both immortalized BMSC (IIS5) and primary patient BMSC. In each case 15 minutes of CC with BMSC (with or without contact) was able to induce phosphorylation of STAT3 in the MM cells, whereas conlemporaneous treatment with CYT387 dramatically reduced the amount of p-STAT3 in the HMCL (Figure IC). Thus, demonstrating that CYT387 is able to prevent STAT3 activation in MM cells induced by the soluble within lhe MM-BMSC microenvironment and also the contact mediated signalling provided to MM by BMSC.
CYT387 inhibits P13K/AKT and Ras/MAPK signalling JAK signalling kinases are involved in many cellular palhways, which lcd us to investigate the effect of CYT387 on IL-6 and IGF-l induced P13K/AKT and Ras/MAPK signalling in NCI11929, OCI-MYI and U266cells (Figure ID). OCl-MYl showed distinct p-AKT activation after IL-6 and IGF-l stimulation that was signifîcantly reduced by CYT387 cotreatment. IL-6 and IGF-l stimulation induced p-ERK in U266 cells which was significantly inhibited by CYT387. l'he levels of p-AKT anti p-ERK showed only a small increase tn response to IL-6 and IGF-l stimulation in NCI-H929.
-22CYT387 inhibits prolifération in HMCL
The effect of CYT387 (O.l - 5 μΜ) on cell prolifération was measured by MTS assay at 24, 48 and 72 hours (Figure 2A) on a panel of 8 HMCL (IL-6 non-responsive phenotype - LP-l, NCI-H929, OPM2, RPMI-8226 and IL-6 responsive phenotype - ANBL-6, OCI-MY l, U266 and XG-l). Six of 8 HMCL had a time and dose dépendent response to CYT387 with inhibition in some HMCL within 24 hours. At 72 hours NCI-H929 and XG-l were the most sensitive to CYT387treatment.
Prolifération of HMCL cultured with CYT387 over 72 hours was also assessed by quantitation of viable cell number by haemocytomelcr (Figure 2B). Because ofthe obvious relationship between IL-6 signalling and the inhibition of JAK2 by CYT387 the prolifération of 3 HMCL (NCI-H929, OCI-MYl and U266) was measured with the addition of IL-6 and/or CYT387. The 3 HMCL proliferated well in complété media with or without supplémentation with 10 ng/ml IL-6 and CYT387 (0.5 - l μΜ) was able to rcduce the prolifération of HMCL in culture even in tlie presence of IL-6. CYT387 inhibited cell prolifération by 50% NCI-H929 (l μΜ). 50% OCl-M Y l (0.5 μΜ) and 44% U266 ( l μΜ) after 72 hours.
Treatment of HMCL with CYT387 results in an accumulation of cells in G2/M phase of the cell cycle
The anti-proliferative effects of CYT387 were further characterised by evaluating the cell cycle of HMCL treated with CYT387. HMCL (NCI-H929, OCI-MYl and Ό266) treated with CYT387 (l - 5 μΜ) showed a marked accumulation of cells in the G2/M phase ofthe cell cycle. This was most pronounced in NCI-H929 cells (Figure 2C), where there was more than a two fold increase in cells in G2/M in the drug treated sample compared to untreated or vehicle treated control after24 and 72 hours treatment. An additional polyploid population was found in the CYT387 treated samples - suggesting thaï CYT387 treatment causes further aberration from the normal cell cycle of MM cells.
CYT387 induces apoptosis in HMCL and primary MM cells
Apoptosis of CYT387 treated cells was investigated using Annexin-V/Propidium Iodide FACS slaining in 3 HMCL (NCIII929, OCI-MYl and U266). An increased proportion of apoptotic cells was detected in ail 3 HMCL which was most évident in NCI-H929 (Figure 3A), with a 2I and 52% réduction in viable cells detected at 24 and 72 hours, respectively, after treatment with 5 μΜ CYT387 (Figure 3B). To assess CYT387 as pari of a combination therapy NCI-H929, OCI-MYl and U266 were treated with a range of doses of CYT387, bortezomib, melphatan to establish dose effect curves for each drug before combining with CYT387 and ineasurîng the synergy using CalcusynTM software. Dose effect curves generaied for each compound (melphalan and bortezomib data not shown) show CYT387 (0.5 - 10 μΜ) induced apoptosis in 3 HMCL in a time and dose dépendent manner (Figure 4A). CYT387 displayed o(
-23 synergism with both bortezomib and melphalan but with variations in the level of synergy seen at differing drug dosages and analysis time-points (Figure 4B).
The effect of CYT387 on ex-νίνο primary MM cells was also investigated, both as a single agent and as part of combination therapy. MM Patient BMA were cultured with various of doses of CYT387 (5 - 50 μΜ) for 24 and 48 hours after wliich the CD38+CD45- MM cell populations were asscssed for apoptosis by flow cytometry. Six patients were treated and apoptosis was seen in between 5 and 59% of MM cells treated with 20 μΜ CYT387 after 48 hours (Figure 5A). The eflect of CYT387 in combination with melphalan and bortezomib was also investigated. CYT387 was seen to synergize with melphalan in 2/3 patients, and synergy was also observed with bortezomib in some patients/doses (Figure 5B).
DISCUSSION
Multiple lines of evidence bave confinned the rôle oflL-6/JAK/STAT signalling in MM including experiments demonstrating lhe IL-6 dependence of some MM cells, the upregulalion of prolifération of MM cells with IL-6, the inhibition of drug induced apoptosis by IL-6, and most important to this investigation, the direct induction of apoptosis in MM cells by inhibition ofthe IL-6/JAK/STAT pathway. These data and the abundance of IL-6 in the BMME makes JAK/STAT signalling a rational target for inhibition with new chemotherapeutics and is supportée! by preliminary in vitro studies that hâve demonstrated MM cell apoptosis induction via siRNA targeting ofthe JAK/STAT pathway [27]. Furthermore, the signal transduction rôle of JAKs în other important pathways [reviewed by 5] and the pro-survival effects of JAK mutations in other haemalologicai malignancies [l-4] hâve already demonstrated the therapeutic potential of JAK inhibition. The therapeutic challenge is then inhibiting MM cells in the presence of IL-6 or BMSC. Here we hâve expanded upon previous work evaluating JAK inhibition in MM by studying a broader range of IIMCL, by demonstrating that CYT387 can inhibit JAK-STAT activation in the context of coculture tnodels and by demonstrating the impact of CYT387 on primary MM tumour cells. It has been hypothesized that in the earlier stages of MM that the malignant cells are predominantly CD45+, whereas in more advanced, drug-resistant disease, CD45- MM cells predominate [28], Moreover, CD45- MM cells are considered less IL-6 responsive and express fewer IL-6 receptors than CD45+ MM [29], Other studies of JAK inhibition bave focuscd predominantly on CD45+ IL-6 responsive I-IMCL and while this is a logical locus for preliminary investigation il must be stressed that such target cell populations represents only a subset of MM cells. Furthermore, patients may demonstrate mixed populations of both C’D45-and CD45+ MM cells [29], Importantly, we bave demonstrated lhe effectiveness of CYT387 against NCI-H929, a IIMCL considered to bave an IL-6 non-responsive phenotype suggesting thaï CYT387 will be effective against a range of MM phenotypes, whereas others [19] bave reported only limited success against CD45- MM
-24using alternative JAK inhibitors. Our data demonslrating synergy between CYT387 and bortezomib or melphalan against several HMCL and primary MM tumour cells confirais previously published work [l 9).
Available data suggests that the inhibition of JAK in MM cells may hâve downstream effects other than the direct inhibition ofthe JAK/STAT pathway. The importance ofIL-6 in MM cell survival has been well characterized in ternis of the JAK/STAT pathway but there is now increasing evidence of lL-6 induced P13K/AKT activation [l 8, 30] and Ras/MAPK activation [20, 30-33] in various IIMCL. Given the established importance of both the PBK/AKT andRas/MAPK pathways in addition to the JAK/STAT pathway in MM, small molécule inhibitors that could modulate ail three could hâve enormous clinical potential.
hivestigating the effects of JAK inhibition on the P13K/AKT and Ras/MAPK pathways has yielded contrasting results. AZD1480 and AG490 bave beeti shown to reduce IL-6 induced activation of Ras/MAPK [20, 22], but AG490 in lhe hands of others showed no decrease in IL-6 induced Ras/MAPK activation [31 ]. The JAK inhibîtor 1NCB20 could inhibit IL-6 induced Ras/MAPK activation in MM.l S cells, but did not affect constitutive Ras/MAPK activation iti lNA-6 cells [l 8]. The inhibition of JAK with AG490 could also abrogate AKT activation in PTEN mutated OPM2 MM cells [30]. Similarly 1NCB20 could also inhibit IL-6 induced pΛΚΤ, but had no effect on IGF-l induced p-AKT in INA-6 cells [l8]. Variability in the available data may be the resuit of différences in inhibitors and heterogeneity amongst HMCLs that are commonly studied. In our study there was a signilicant réduction in IL-6 and IGF-l induced ρ-ERK in U266 cells, as well as a dramatic réduction of IL-6 and IGF-l induced pAKT in OCIMYl cells supporting the data of others that suggests JAK inhibition may hâve broader anti-MM activity than would be initially expected. The inhibition of IL-6 induced JAK/STAT and PI3K/AKT signalling may also resull in a réduction in IL-6R expression on the surface of MM cells [30], which could also lead to a réduction in the pro-survival effects of IL-
6.
The profound anti-proliferative effect of CYT387 on various HMCL after a single dose is an important démonstration of its elTectiveness. Furthermore, the ability of CYT387 lo inhibit HMCL growth even in the presence ofexogenous IL-6 which has been shown many limes as a medialor of drug résistance [l 1-13] ts noteworthy. This signilicant effect of JAK inhibition may be the result of HMCL having some dependence on JAK/STAT for proliférative signais, or more likely the involvement and subséquent inhibition of alterative signalling pathways mentioned above. The effect on prolifération is also seen in the cell cycling analysis which demonslrates that CYT387 can prevent cell cycling.
Also of interest was lhe additional polyploidy population (8n) induced by CYT387 treatment, which may suggest a rôle for JAK signalling leading to cell cycle régulation or may be the resuit of CYT387 inhibition of other kinases involved in cell cycle such as aurora B,
-25 aurora C, cyclin A or cyclin B as described by Pardanani et aL, 2009. A direct or downstream effect of JAK inhibitors on cell cycling proteins is supported by studies on other JAK inhibitors; Scuto et al. found AZD1480 inhibited Cyclin D2 in two HMCL [22]. The induction of apoptosis in MM cells in primary marrow cocultures is a critical démonstration of the potential of CYT387. In contrast, other studies inhibiting IL-6 signalling hâve failed to demonstrate any convincing evidence of apoptosis when MM cells were treated in the presence of BMSC [32]. The investigators suggested that this might represent MM cell independence from IL-6 in the presence of BMSC. Our findings with CYT387 could bc interpreted as either refuting the latter or alternatively being consistent with the capacity of JAK signalling inhibition to interrupt non1L6 mediated survival pathways. Consistent with the latter was that the primary MM samples treated with CYT387 were représentative of autologous whole marrow cocultures with lhe CD38+CD45- MM cells making up between 4 and 67% of treated cells. Therefore the démonstration that CYT387 was able to induce apoptosis of these heavily-treated MM cells was particularly encouraging.
Additional compound évaluation
The compounds of formula lb can tested in the mouse model of multiple myeloma as described in Dalton, W. and Anderson, K. C., Clinical Cancer Rcsearch, 2006; 12(22), 66036610. Mouse models 5T2MM and 5T33MM are reported in Dalton et al as having clinical characteristics similar to the human disease, including localisation of multiple myeloma cells to the bone marrow, measurable M-protein in sérum, induction of osteolytic bone disease, and increased angiogenesis in the marrow. Both models may therefore be used to test the compounds of formula lb and allow for lestîng whether the compounds affect multiple myeloma cell homing before disease onset or after onset ofthe disease. Using these models, the effect ofthe compounds on lhe levels of sérum M-protein may be determined and the effect of the compounds on inhibition of disease development such as réduction of osteolytic bone disease, réduction in tumor burden and improvement in survival, may also be determined.
In order to examine the effects ofthe compounds of formula lb against a human myeloma, the compounds may be tested against xenograft models of human myeloma in mice. For these tests, the xenograft models of human myeloma turmors or cell lines may be transplanted into, for example, SCID-Ilu or NOD/SCID mice. The SCID-lIu model may be used to study myeloma in a human microenvironmenl and the impact of lhe compounds of formula lb on the reproducible growth of primary myeloma cells may also be studied. The NOD/SCID model involves labelling multiple myeloma cells with green fluorescent protein. This model may be used to follow disease progression. j
-26REFERENCES
1. Kralovics, R., F. Passamonti, A.S. Buser, et al., J gain-of-fiinction mutation ofJAK.2 in myeloproliferativedisorders. N Engl J Med, 2005. 352(17): p. 1779-90.
2. Levîne, R.L., M. Wadleigh, J. Cools, et al., Aclivating mutation in the tyrosine kinase JAK2 in polycythemia vera.essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005.7(4): p. 387-97.
3. Scott, L.M., W. Tong, R.L. Levîne, et al„ JAK2 exon 12 mutations inpolycythemia vera and idiopathicerythrocytosis. N Engl J Med, 2007. 356(5): p. 459-68.
4. Mullighan, C.G., J. Zhang, R.C. Harvey, et al„ JAK mutations in high-risk childhood acute lymphoblasticleukemia. ProcNatlAcadSci USA, 2009. 106(23): p. 9414-8.
5. Rane, S.G. and E.P. Rcddy, Janus kinases: components of multiple signalingpathways, Oncogene, 2000.19(49):p. 5662-79.
6. French, J.D., D.K. Walters, and D.F. Jelinek, Transactivation of gpl30 in myeloma cells. J Immunol, 2003.170(7): p. 3717-23.
7. Berger, L.C., T.S. Hawley, J.A. Lusl, S.J. Goldman, and R.G, Hawley, Tyrosine phosphorylation of JAK-TYKkinases in malignant plasma cell lines growth-stimulated by interleukins 6and II. BiochcmBiophys ResCommun, 1994.202(1): p. 596-605.
8. Gomez-Benilo, Μ., P. Balsas, X. Carvajal-Vergara, et al., Mechanism of apoptosis induced by IFN-alpha inhuman myeloma cells: rôle ofJakl and Bint andpotentiation by rapamycin. Cell Signal, 2007.19(4): p. 844-54.
9. Jelinek, D.F., G.J. Ahmann, P.R. Greipp, et al., Coexistence ofaneuploidsubclones within a myeloma cell linetliat exhibits clonal immunoglobulin gene rearrangement: ciinical implications. Cancer Res, 1993.53(21): p.5320-7.
10. Zhang, X.G., J.P. Gaillard, N. Robillard, et al., Reproducible obtaining of human myeloma cell lines as a modelfor tumor stem cell study in human multiple myeloma. Blood, 1994.83( 12): p. 3654-63.
11. Cheung, W.C. and B. Van Ness, The bone marrow stromal microenvironment influences myeloma therapeuticrespon.se in vitro. Leukemia, 2001.15(2): p. 264-71.
12. Moreaux, J., E. Legout'fe, E. Jourdan, et ah, BAFFand APR1Lprotect myeloma cellsfrom apoptosis induced byinterleukin 6 deprivation and déxaméthasone. Blood, 2004.103(8): p. 3148-57.
13. Perez, L.E., N. Parquet, K. Shain, et al., Bone marrow stroma confers résistance to Apo2 Ugand/TRAIL inmidtiple myeloma in part by regulating c-FLIP. J Immunol, 2008.180(3): p. 1545-55.
14. Klein. B.. X.G. Zhang. M. Jourdan, et al., Paracrine rallier than autocrine régulation of myeloma-cell growth anddifferentiation by interleukin-6. Blood, 1989.73(2): p. 517-26. pZ
15. Tyner, J.W., T.G. Bumm, J. Deîninger, et al., CYT387, a novel JAK2 inhibitor, induces hématologie responsesand normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood, 2010.115(25): p. 5232-5240.
16. Pardanani, A., T. Lasho, G. Smith, C.J. Burns, E. Fantino, and A. Tefferi, CYT387, a sélective JAK17JAK2inhibitor: in vitro assessment of kinase selectivity andpreclinical studtes using cell lines andprimary cellsfrompolycythemia vera patients. Leukemia, 2009.23(8): p. 1441-5.
17. Burns, C.J., D.G. Bourke, L. Andrau, et al., Phenylaminopyrimidines as inhibitors ofJanus kinases (JAKs).Bioorg Med ChemLett, 2009. 19(20); p. 5887-92.
18. Burger, R., S. Le Gouill, Y.T. 'Fai, et al., Janus kinase inhibitor INCB20 has antiproliférative and apoptoticeffects on human myeloma cells in vitro and in vivo. Mol Cancer Ther, 2009.8(1): p. 26-35.
19. Li, J., M. Favata, J.A. Kelley, et al., INCBi6562, a JAKI/2 sélective inhibitor, is efficacious against nudtiplemyeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia, 2010.12(1): p.28-38.
20. De Vos, J., M. Jourdan. K. 'Parte, C. Jasmin, and B. Klein, JAK2 tyrosine kinase inhibitor tyrphostin AG490downregulates the mitogen-activatedprotein kinase (MARK) and signal transducer and activator of transcription(STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol, 2000.109(4): p. 823-8.
21. Alas, S. and B. Bonavida, Inhibition of constitutive STAT3 activity sensitizes résistant nonHodgkin's lymphomaand multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res, 2003.9(1): p. 316-26.
22. Scuto, A., P. Krcjci, L. Popplewell, et al., The novel J AK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling,resulting in suppression of human myeloma cell growth and survival. Leukemia, 2010.
23. Pedranzini, L., T. Dechow, M. Berishaj, et al., Pyridone 6, a pan-Janus-activatedkinase inhibitor, inducesgrowth inhibition of multiple myeloma cells. Cancer Res, 2006.66( 19): p. 9714-21.
24. FeiTajoli, A., S. Faderl, Q. Van, et al., IVP1066 disrupts Janus kinase-2 and induces caspase-depeudent apoptosisin acute myelogenous leukemia cells. Cancer Res, 2007.67(23): p. 11291-9.
25. Khong, T., J. Sharkey, and A. Spencer, The eflect of azacitidine on interleukin-6 signaling and nuclear factorkappaBactivation and its in vitro and in vivo activity against multiple myeloma. Haematologica, 2008.93(6): p.860-9.
26. Monaghan, K., T. Khong, G. Smith, and A. Spencer, CYT997 Causes apoptosis in human multiple myeloma.Invest New Drugs, 2009.
27. Chatteijee, Μ., T. Stulimer, P. Herrmann, K. Bommert, B. Dorken, and R.C. Bargou,
Combined disruption ojboth the MEK/ERKand the IL-6R/STAT3pathways is required to induce apoptosis of multiple myeloma celh inthe presence ofbone marrow stromal cells. Blood, 2004.104(12): p. 3712-21.
28. Kumar, S., S.V. Rajkumar, T. Kimlinger, P.R. Greipp, and T.E. Witzig, CD45 expression by bone marrowplasma cells in multiple myeloma: clinical and biological corrélations. Leukemia, 2005.19(8): p. 1466-70.
29. Ilata, H., II. Xiao, M.T. Pétrucci, J. Woodliff, R. Chang, and J. Epslein, Interleukin-6gene expression in multiplemyeloma: a characteristic of immature tumor cells. Blood, 1993.81( 12): p. 3357-64.
30. Thabard, W., M. Collette, M.P. Mellerin, et al., IL-6 upregulates its own receptor on some human myeloma celllines. Cytokine, 2001.14(6): p. 352-6.
31. Puthier, D., R. Bataille, and M. Amiot, IL-6 up-regulates md-l in human myeloma cells through J AK / STATrather than ras / MAP kinase pathway. Eur J Immunol, 1999. 29(12): p. 3945-50.
32. Chatterjee, M., D. Honemann, S. Lentzsch, et al., In the presence ofbone marrow stromal cells human multiplemyeloma cells become independent ofthe IL-6/gpl 30/STAT3 pathway. Blood, 2002.100(9): p. 3311-8.
33. Ferlin, Μ., N. Noraz, C. I-Iertogh, J. Brochier, N. Taylor, and B. Klein, Insulin-likegrowth factor induces thesurvival and prolifération of myeloma cells through an interleukin-6independent transductionpathway. Br JHaematol, 2000.111(2): p. 626-34. cf
-29l. The use of a compound in preparing a médicament for treating a subject presenting with multiple myeloma at a stage characterized by an increase in the prevalence of MM cells that (l) are IL-6 non-responsive and/or (2) hâve a CD45- phenotype, the compound having the formula Ib:
Claims (10)
- WE CLAIM:whereinZ is independently selected from N and Cil;R1 is independently selected from H, halogen, OH, CON11R*. CON(R2)2, CF», R2 * *OR2 *, CN, morpholino, thiomorpholinyl, thiomorpholino-l, l-dioxide, substituted or unsubstitutedpiperidinyl, substituted or unsubstitutcdpipcrazinyl, imidazolyl, substituted or unsubstitutedpynOlidinyl and Cj^alkylene wherein the carbon atoms are optionally replaced with NRV and/or O substituted with morpholino, thiomorpholinyl, thiomorpholino-l, l-dioxide, substituted or unsubstitutedpiperidinyl, substituted or unsubstitutedpiperazinyl, imidazolyl or substituted or unsubstitutedpynOlidinyl;R2 is substituted or unsubstituted C|.qalkyl;RY is H or substituted or unsubstituted Cj^alkyl;R8 is RXCN;Rx is substituted or unsubstituted Ci^alkylene wherein up to 2 carbon atoms can be optionally replaced with CO, NSO2R', NRY, CONRY, SO, SO2 or O;R11 is II or Ci^alkyl, or an enantiomer thereof, a prodrug thereof or a pharmaceutically acceptable sait thereof effective to reduce the viability of said MM cells.
- 2. The use of a compound of in preparing a médicament for treating a subject with multiple myeloma according to claim 19 including the steps of (1) selecting, for treatment, a subject diagnosed with an increase in the prevalence of MM cells that ( i ) are IL-6 non-responsive, and/or (2) hâve a CD45- phenotype; and (2) administering to the subject an amount the compound of formula 1b effective to reduce the viability of the MM cells.
- 3. The use of a compound of in a method of preparing a médicament for treating a subject with multiple myeloma according to claim 20, including the steps of ( l ) obtaining a sample of MM cells front said subject; (2) analyzing said MM cells for the prevalence of cells that are IL-6 non-responsive and/or have a CD45- phenotype; (3) selecting for treatment a subject in which the prevalence of said MM cells is increased relative to subjects at an early stage of multiple myeloma, and (4) administering to the selected subject an amount of the compound of formula Ib effective to reduce the viability of said MM cells.
- 4. The use of a compound in preparing a médicament for use in treating a subject presenting with multiple myeloma according to any one of daims 19 to 21, wherein the subject is treated with CYT 387 which is N-(cyanomethyl)-4-[2-[[4-(4morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide, having the structure shown below:CN , or an enantiomer thereof, a prodrug thereof or a pharmaceutically acceptable sait thereof
- 5. The use of a compound in preparing a médicament for use in treating a subject presenting with multiple myeloma according to claim 22, wherein the subject is afflicted with newly diagnosed or relapsed multiple myeloma.
- 6. The use of a compound in a method of preparing a médicament for use in treating a subject with multiple myeloma according to any one of daims 18 to 23 wherein the subject présents with a population of MM cells in which at least I0% of said cells are CD45-.
- 7. The use of a compound in a method of preparing a médicament lor use in treating a subject with multiple myeloma according lo daim 24, wherein the subject is treated with CYT 387 and a second therapeutic agent selected from mclphalan and bortezomib.-3l -
- 8. An article of manufacture, comprising a container comprising the compound of formula Ib defined in claim l, and, associated with the container, a label indicating treatment of a subject presenting with newly diagnosed or relapsed multiple myeloma in which MM cells are IL-6 non-responsive or hâve a CD45- phenotype.
- 9. A kit comprising a container comprising the compound of formula Ib defined in claim l in an amount useful to trcat newly diagnosed or relapsed multiple myeloma in which MM cells are IL-6 non-responsive or bave a CIJ45- phenotype and, in association
- 10 lherewith, printed instruction teaching a method according to any one of claims 1 -7. p/
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/481,425 | 2011-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA16774A true OA16774A (en) | 2016-01-04 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20140171433A1 (en) | Multiple myeloma treatment | |
US20140073643A1 (en) | Treatment of jak2-mediated conditions | |
KR101781654B1 (en) | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies | |
RU2598852C2 (en) | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity | |
SK185399A3 (en) | COMPOSITIONS AND METHODS FOR REDUCING RESPIRATORY DEPRESSION ANDì (54) ATTENDANT SIDE EFFECTS OF MU OPIOID COMPOUNDS | |
US11446301B2 (en) | Quinoline analogs as phosphatidylinositol 3-kinase inhibitors | |
EP3265093A1 (en) | Tricyclic kinase inhibitors of melk and methods of use | |
EP2906564A1 (en) | Treating brain cancer using agelastatin a (aa) and analogues thereof | |
AU2017271550B2 (en) | Method of treating cancer by targeting myeloid-derived suppressor cells | |
US11872220B2 (en) | Methods and compositions for treating B-cell malignancies | |
OA16774A (en) | Multiple myeloma treatment. | |
CA3196283A1 (en) | Csf1r kinase inhibitor and use thereof | |
RU2776899C2 (en) | Method for treating cancer by targeting suppressor cells of myeloid origin | |
WO2021197334A1 (en) | Pharmaceutical combination and use thereof |